You Shoujiang, Yin Xiaowei, Liu Huihui, Zheng Danni, Zhong Chongke, Du Huaping, Zhang Yu, Zhao Hongru, Qiu Chenhong, Fan Liangfeng, Pei Shaofang, Ma Zhaoxi, Cao Yongjun, Liu Chun-Feng
Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou 215004. China.
The George Institute for Global Health, University of New South Wales, Sydney 2050, NSW. Australia.
Curr Neurovasc Res. 2017;14(3):242-249. doi: 10.2174/1567202614666170621103604.
The impact of hyperfibrinogenemia on short-term outcomes after acute ischemic stroke (AIS) is still not well understood.
We investigated the association between hyperfibrinogenemia upon hospital admission and the short-term prognosis of AIS patients.
A total of 3,212 AIS patients enrolled from December 2013 to May 2014 across 22 hospitals in Suzhou city were included in the present study. Hyperfibrinogenemia was defined as having a serum fibrinogen>4.0g/L. Cox proportional hazard and logistic regression models were used to estimate the effect of hyperfibrinogenemia on all-cause in-hospital mortality and poor discharge outcome (modified Rankin Scale score≥3) in AIS patients.
During hospitalization, 106 patients (3.3%) died from all-cause and 1226 (38.2%) patients experienced poor functional outcome at discharge. Multivariable model adjusted for age, sex, baseline National Institutes of Health Stroke Scale score, white blood cell count and other covariates, showed that hyperfibrinogenemia was associated with a 1.76-fold increase in the risk of in-hospital mortality (hazard ratio [HR] 1.76; 95% confidence interval [CI], 1.10-2.81; P-value=0.019). However, there was no significant association between hyperfibrinogenemia and poor outcome at discharge (adjusted odds ratios[OR]1.15; 95% CI 0.86-1.53; P-value=0.338). Sensitivity and subgroup analyses also confirmed a significant association between hyperfibrinogenemia and in-hospital mortality.
In patients with AIS, hyperfibrinogenemia at the time of admission was independently associated with increased in-hospital mortality.
高纤维蛋白原血症对急性缺血性卒中(AIS)后短期预后的影响仍未完全明确。
我们研究了入院时高纤维蛋白原血症与AIS患者短期预后之间的关联。
本研究纳入了2013年12月至2014年5月期间在苏州市22家医院登记的3212例AIS患者。高纤维蛋白原血症定义为血清纤维蛋白原>4.0g/L。采用Cox比例风险模型和逻辑回归模型评估高纤维蛋白原血症对AIS患者全因住院死亡率和不良出院结局(改良Rankin量表评分≥3)的影响。
住院期间,106例患者(3.3%)全因死亡,1226例患者(38.2%)出院时功能结局不良。多变量模型对年龄、性别、基线美国国立卫生研究院卒中量表评分、白细胞计数和其他协变量进行了调整,结果显示高纤维蛋白原血症与住院死亡率风险增加1.76倍相关(风险比[HR]1.76;95%置信区间[CI],1.10 - 2.81;P值 = 0.019)。然而,高纤维蛋白原血症与出院时不良结局之间无显著关联(调整后的比值比[OR]1.15;95% CI 0.86 - 1.53;P值 = 0.338)。敏感性分析和亚组分析也证实了高纤维蛋白原血症与住院死亡率之间存在显著关联。
在AIS患者中,入院时的高纤维蛋白原血症与住院死亡率增加独立相关。